Immunizations, neonatal jaundice, and animal-induced injuries

Current Opinion in Pediatrics

Volumn 17, Issue 3, 2005, Pages 418-429

  Lee, Melissa S ^a   Bernstein, Henry H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Animal bites; Hyperbilirubinemia; Immunizations; Jaundice

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

BITE; BREAST FEEDING; CHICKENPOX; DOG BITE; FEVER; FOLLOW UP; GESTATIONAL AGE; HAND WASHING; HEALTH EDUCATION; HOME CARE; HUMAN; HYPERBILIRUBINEMIA; IMMUNIZATION; INFECTION RISK; INJECTION SITE REACTION; NEWBORN JAUNDICE; OTITIS MEDIA; PRIORITY JOURNAL; RABIES; RASH; REPTILE; REVIEW; RISK ASSESSMENT; SALMONELLA; SEIZURE; SPIDER BITE; STREPTOCOCCUS INFECTION;

ANIMALS; ARACHNIDISM; CHICKENPOX VACCINE; GESTATIONAL AGE; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HUMANS; HYPERBILIRUBINEMIA; IMMUNIZATION PROGRAMS; INFANT, NEWBORN; INFLUENZA VACCINES; JAUNDICE, NEONATAL; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; RABIES; SALMONELLA INFECTIONS; SNAKES; UNITED STATES; VACCINATION; VACCINES, CONJUGATE; VIRUS DISEASES;

EID: 20344383760     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200506000-00016     Document Type: Review

References (77)

1. Mell LK, Ogren DS, Davis RL, et al. Compliance with national immunization guidelines for children younger than 2 years, 1996-1999. Pediatrics 2005; 115:461-468. Data are presented to support continued education efforts to increase national compliance.
2. Glazner JE, Beaty BL, Pearson KA, Berman S. The cost of giving childhood vaccinations: differences among provider types. Pediatrics 2004; 113: 1582-1587. Given declining reimbursement rates and increasing costs for administration of pediatric vaccines, the trend may be towards referrals towards lower-cost, public health clinic administration of vaccines.
3. Santoli JM, Huet NJ, Smith PJ, et al. Insurance status and vaccination coverage among US preschool children. Pediatrics 2004; 113:1959-1964.
4. Smith PJ, Chu SY, Barker LE. Children who have received no vaccines: who are they and where do they live? Pediatrics 2004; 114:187-196.
5. Rosenthal J, Rodewald L, McCauley M, et al. Immunization coverage levels among 19 to 35 month old children in 4 diverse, medically underserved areas of the United States. Pediatrics 2004; 113:e296-e302.
6. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, January-June 2004. MMWR Morb Mortal Wkly Rep 2004; 53:Q1-Q4.
7. Centers for Disease Control and Prevention. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2004; 53(RR06):1-40. Extensive review of 2004 recommendations for influenza vaccination, treatment, and management of high-risk groups.
8. Centers for Disease Control. Recommended childhood and adolescent immunization schedule: United States, July-December 2004. MMWR Morb Mortal Wkly Rep 2003; 53:Q1-Q3.
9. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. Pediatrics 2005; 115:453-461. Reassuring data from the Vaccine Adverse Event Reporting System between 1990-2003 support the safety of trivalent influenza vaccination of healthy 6-month-old to 23-month-old infants and children.
10. American Academy of Pediatrics. Recommendations for influenza immunization of children. Pediatrics 2004; 113:1441-1447. Healthy children and infants ages 6-24 months of age should be vaccinated against influenza. A review of influenza vaccine recommendations and use of inactivated vs live-attenuated influenza vaccine.
11. Centers for Disease Control and Prevention. Updated interim influenza vaccination recommendations: 2004-05 influenza season. MMWR Morb Mortal Wkly Rep 2004; 53:1183-1184.
12. Centers for Disease Control and Prevention (CDC). Experiences with obtaining influenza vaccination among persons in priority groups during a vaccine shortage: United States, October-November, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1153-1155. Behavioral Risk Factor Surveillance System, a monthly telephone survey, collected data on self-reported influenza vaccination.
13. Centers for Disease Control and Prevention. Estimated influenza vaccination coverage among adults and children - United States, September 1 -November 30, 2004. MMWR Morb Mortal Wkly Rep 2004; 93:1147-11 53. Harvard School of Public Health telephone survey.
14. Kempe A, Dale MF, Barrow J, et al. Implementation of universal influenza immunization recommendations for healthy young children: results of a randomized, controlled trial with registry-based recall. Pediatrics 2005; 115:146-154.
15. Advisory Committee on Immunization Practices (ACIP). Prevention of varicella: recommendations of the. MMWR Recomm Rep 1999; 48(RR-6):1-5.
16. Nguyen HQ, Jumaan AO, Seward JG. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-458. Evaluation of mortality rates after the introduction of the universal vaccination program against varicella, based on reports of death secondary to varicella as an underlying or contributing cause.
17. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:664-666.
18. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114:786-692.
19. Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era J Pediatr 2004; 144:68-74. Reduced rates of invasive bacterial infections in the setting of varicella immunizations.
20. st century. Pediatr Infect Dis J. 2004; 23:871-872.
21. Vazquez M, Shapiro E. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005; 352:439-440.
22. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851-855. Study of patients over 6 years after varicella vaccine was introduced. Vaccine is 97% effective after the 1st year and only 87% effective 2-8 years after vaccination. Efficacy was also improved in the 1st year after vaccination if given after 15 months of age.
23. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 2005; 24:10-16.
24. Kaplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumocococcal conjugate vaccine. Pediatrics 2004; 113(3 part 1):443-449.
25. Schutze GE, Tucker NC, Mason EO. Impact of the conjugate pneumococcal vaccine in Arkansas. Pediatr Infect Dis J 2004; 23:1125-1129. A study comparing invasive pneumococcal infections between 1998-2000 and 2001-2003, after the AAP recommended the use of a heptavalent conjugate pneumococcal vaccine. The incidence of invasive disease decreased from 5.78/ 100 000 population to 3.02/100 000 population (P = 0.002). It is of concern that the number of cases of invasive isolates not covered by the vaccine is on the rise.
26. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004; 23:1015-1022.
27. Hsu K, Pelton S, Karumuri S. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005; 24:17-23.
28. Lee KC, Finkelstein JA, Miroshnik Z, et al. Pediatricians' self-reported clinical practices and adherence to national immunization guidelines after the introduction of pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med 2004; 158:695-701.
29. Block SL, Hedrick J, Harrison CJ. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23:829-833.
30. Brouwer CNM, Maille AR, Rovers MM, et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics 2005; 115:273-279. Children with recurrent acute otitis media do not have improved quality of life in the post - pneumococcal vaccination era.
31. Vieusseux M. Memoire sur la maladie qui a regne a Geneve au printemps de 1805 [in French]. J Med Chir Pharmacol. 1805; 11:163.
32. Weichselbaum A. Ueber die Aetiologie der akuten Meningitis cerebrospinalis [in German]. Fortschr Med 1887; 5:573-583.
33. Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23:3274-3279. A review of the global impact of meningococcal disease and the current available vaccines.
34. Offit PA, Peter G. The meningococcal vaccine: public policy and individual choices. N Engl J Med 2003; 359:2253-2256.
35. Rosenstein N, Perkins B, Stephens D. Meningococcal disease. N Engl J Med 2001; 344:1378-1388.
36. Muller E, Apicella MA. T-cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide. Infect Immun 1988; 56:259-266.
37. Taylor CE, Bright R. T-cell modulation of the antibody response to bacterial polysaccharide antigens. Infect Immun 1989; 57:180-185.
38. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62. New quadrivalent conjugate vaccines against Meningococcus offer improved immunogenic responses compared with polysaccharide vaccines, without jeopardizing patient safety.
39. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000; 19:333-345.
40. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(suppl 1):S58-S67.
41. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 369: 1829-1831.
42. MacLennan JM, Shackley F, Health PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized control trial. JAMA 2000; 283:2795-2801.
43. DeWals P. Meningococcal C vaccines: the Canadian experience. Pediatr Infect Dis J 2004; 23:3280-3284. A review of the two Canadian mass vaccination campaigns against meningococcal disease using a plain polysaccharide and a conjugate polysaccharide vaccine, with evaluation of cost effectiveness.
44. De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup c meningococcal conjugate vaccine. JAMA 2004; 292:2491-2494. Study of the Canadian mass vaccination campaign against Meningococcus using a conjugated polysaccharide vaccine.
45. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367.
46. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004; 23(12 Suppl): S285-S292. An evaluation of vaccine development, past and present, with thoughts towards future vaccine development against serogroup B meningococcal disease.
47. Bialek SR, Thoroughman DA, Hu D, et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 2004; 94:996-1001. The incidence of hepatitis A infection among American Indian and Alaskan natives has declined with the recommendation of routine hepatitis A vaccination in children since 1996.
48. Usonis V, Bakasenas V, Valentelis R, et al. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 2003; 21:4588-4592.
49. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415-1420.
50. Bhutani VK, Johnson LH, Maisels MJ, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004; 24:650-662. Summary of challenges associated with preventing kernicterus.
51. Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004; 114:e130-e153. An extensive review of the literature regarding neonatal hyperbilirubinemia.
52. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Clinical practice guideline: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297-316. New clinical practice guidelines for the prevention and management of hyperbilirubinemia, updated from 1994.
53. Garg AK, Prasad RS, Hifzi IA. A controlled trial of high-intensity double-surface phototherapy on a fluid bed versus conventional phototherapy in neonatal jaundice. Pediatrics 1995; 95:914-916.
54. Tan KL. Comparison of the efficacy of fiberoptic and conventional phototherapy for neonatal hyperbilirubinemia. J Pediatr 1994; 125:607-612.
55. Maisels MJ, Kring E. Bilirubin rebound following intensive phototherapy. Arch Pediatr Adolesc Med 2002; 156:669-672.
56. Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 2000; 154:1140-1147.
57. Newman TB, Escobar GJ, Gonzales VM, et al. Frequency of neonatal bilirubin testing and hyperbilirubinemia in a large health maintenance organization. Pediatrics 1999; 104:1198-1203.
58. Palmer RH, Keren R, Maisels MJ, Yeargin-Allsopp M. National Institute of Child Health and Human Development (NICHD) conference on kernicterus: a population perspective on prevention of kernicterus. J Perinatol 2004; 24:723-725. Issues presented at the NICHD conference on bilirubin-induced brain injury and kernicterus, including barriers to following published guidelines for the management of hyperbilirubinemia.
59. Escobar GJ, Greene JD, Hulac P, et al. Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. Arch Dis Child 2005; 90:125-131. A large study of live births in the Kaiser Permanente Medical Care Program examining causes and risk factors for rehospitalization of neonates in the first 2 weeks of life.
60. Sarici SU, Muhittin AS, Korkmaz A, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics 2004; 113:775-780. A prospective study of term vs near-term infants, evaluating risk factors for hyperbilirubinemia and development of a normogram for serum bilirubin levels in near-term infants based on post-natal age.
61. Stevenson DK, Wong RJ, Vrema HJ, et al. NICHD conference on kernicterus: research on prevention of bilirubin-induced brain injury and kernicterus: bench-to-bedside: diagnostic methods and prevention and treatment strategies. J Perinatol 2004; 24:521-525. Discussion of bilirubin metabolism and potential targets for therapy.
62. Slusher TM, Angyo IA, Bode-Thomas F, et al. Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants. Pediatrics 2004; 113:1636-1641. Transcutaneous bilirubin measurements can be used in areas with limited laboratory resources, even in more darkly pigmented skin types; study limited by small sample size.
63. Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005; 159:113-119. Clinical risk factors and laboratory measurement of serum bilirubin are better predictors of hyperbilirubinemia when used together.
64. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics 2004; 113:119-123.
65. Croen LA, Yoshida CK, Odouli R. Neonatal hyperbilirubinemia and risk of autism spectrum disorders. Pediatrics 2004; 115:e135-e138.
66. Kozak LJ, Hall MJ, Owings MF. National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2002; 153:1-194.
67. Paul IM, Phillips TA, Widome MD, et al. Cost-effectiveness of postnatal home nursing visits for prevention of hospital care for jaundice and dehydration. Pediatrics 2004; 114:1015-1022. Model to assess cost effectiveness of home nurse visits on emergency department visits and rehospitalization in the first 10 days of life.
68. Rupprecht CE, Gibbons RV. Prophylaxis against rabies. N Engl J Med 2004; 351:2626-2635. Review of the indications for rabies prophylaxis.
69. Krebs JW, Long-Marin SC, Childs JE. Causes, costs, and estimates of rabies post-exposure prophylaxis treatments in the United States. J Public Health Manag Pract 1998; 4:56-62.
70. Hankins DG, Rosekrans JA. Overview, prevention, and treatment of rabies. Mayo Clin Proc 2004; 79:671-676.
71. Centers for Disease Control. Recovery of a patient from clinical rabies: Wisconsin, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1171-1173.
72. Isbister GK. Prospective cohort study of definite spider bites in Australian children. J Paediatr Child Health 2004; 40:360-364.
73. Hover NG, Fortenberry JD. Use of antivenin to treat priapism after a black widow spider bite. Pediatrics 2004; 114:e128-e129.
74. Mold JW, Thompson DM. Management of brown recluse spider bites in primary care. J Am Board Fam Pract 2004; 17:347-352.
75. Feldman KA, Trent R, Jay MT. Epidemiology of hospitalisations resulting from dog bites in California, 1991-1998. Am J Public Health 2004; 94:1940-1941.
76. Schröter M, Roggentin P, Hofmann J, et al. Pet snakes as a reservoir for Salmonella enterica subsp. diarizonae (serogroup IIIb): a prospective study. Appl Environ Microbiol 2004; 70:613-615.
77. Anindya C, Dev PR, Vijaya S. Surgical implications of snakebites. Indian J Pediatr 2004; 71:379-399.